CSIMarket Company Name, Ticker, Suppliers, else..
 
Biomx Inc  (PHGE)
 
Price: $0.1425 $0.00 -0.350%
Day's High: $0.14499999582767487 Week Perf: 7.95 %
Day's Low: $ 0.13 30 Day Perf: -22.13 %
Volume (M): 3,335,768 52 Wk High: $ 12.29
Volume (M$): $ 0 52 Wk Avg: $3.91
Open: $0.14 52 Wk Low: $0.12



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 10
 Employees 20
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -35
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a clinical-stage product discovery firm focused on developing phage-based therapies using natural and engineered bacteriophages to target bacteria associated with chronic diseases such as diabetic foot infections. It develops two types of phage therapies: fixed cocktail therapies for broad patient populations and personalized therapies matched to individual patients through proprietary testing. Its product candidates, including BX011 and BX211, are in clinical development targeting infections caused by Staphylococcus aureus. The company currently has no approved products or revenue.




   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
APGE        0.09% 
FDMT   -3.98%    
IBRX   -3.64%    
IVVD   -10.86%    
MRNA        0.77% 
STRO   -4.48%    
• View Complete Report
   



Clinical Study

Navigating New Frontiers in Phage Therapy BiomXs Innovative Approaches in Treating Diabetic Foot Osteomyelitis and...

Published Mon, May 19 2025 3:46 PM UTC

BiomX Inc. a clinical-stage company specializing in phage therapy, continues to make strides in developing innovative treatments targeting pathogenic bacteria associated with chronic diseases. This article outlines the recent advancements seen in BiomX s clinical trials, focusing on the positive outcomes for BX211 in diabetic foot osteomyelitis (DFO) and BX004 in cystic fi...
Management Announcement

BiomX Inc. on the Rise: Navigating Challenges and Driving Innovation in Biotech

Published Mon, Mar 31 2025 10:31 AM UTC

Outline of Facts:1. Positive Phase 2 Trial Results: - BiomX announced positive topline results from its Phase 2 trial evaluating BX211 for the treatment of Diabetic Foot Osteomyelitis (DFO). - A conference call and webcast are scheduled to discuss the results, demonstrating proactive engagement with stakeholders.2. Return on Assets (ROA): - For Q4 2024, BiomX reported ...
Stock Market Announcement

BiomX Regains NYSE Compliance and Advances Cystic Fibrosis Treatments with Phage Therapy

Published Mon, Dec 16 2024 1:00 PM UTC

BiomX Inc. Reclaims NYSE Standing as Cystic Fibrosis Treatments Take Center StageNESS ZIONA, Israel - December 16, 2024 - BiomX Inc. (NYSE American: PHGE), a clinical-stage biotechnology company recognized for advancing innovative natural and engineered phage therapies aimed at targeting specific pathogenic bacteria, has recently announced a significant milestone in its corp...
Clinical Study

In a significant development for cystic fibrosis (CF) management, BiomX Inc. a company at the ...

Published Wed, Sep 18 2024 12:00 PM UTC

A New Frontier in Cystic Fibrosis Treatment: BiomX s Promising Data on BX004:In a significant development for cystic fibrosis (CF) management, BiomX Inc. a company at the forefront of phage therapy exploration, is set to present promising updates concerning its clinical trial on BX004. The findings will be featured at the North American Cystic Fibrosis Conference, underscori...
Clinical Study

Hope on the Horizon BiomX’s Promising Advances in Phage Therapy for Cystic Fibrosis

Published Tue, Sep 3 2024 12:01 PM UTC

Cystic fibrosis (CF) remains a formidable challenge in respiratory medicine, characterized by chronic pulmonary infections most commonly associated with Pseudomonas aeruginosa . Recent developments from BiomX Inc. a pioneering clinical-stage company, promise to transform treatment paradigms through the innovative use of phage therapy. This article delves into the implicati...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4.43
Price to Sales (Expected) -
Price to Book 0.08
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.06
Working Capital Ratio 0.24
Leverage Ratio (MRQ) 0.98
Total Debt to Equity 0.03
Interest Coverage (TTM) -
Debt Coverage (TTM) 31.61

Per Share Current
Earnings (TTM) -15.55 $
Revenues (TTM) 0.03 $
Cash Flow (TTM) -
Cash 0.06 $
Book Value 1.71 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 16,600
Net Income per Employee (TTM) -1,730,050
Receivable Turnover Ratio (TTM) 4.06
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) 29.22 %
Operating Margin (MRQ) -1630.72 %
Net Margin (MRQ) -1158.43 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Biomx Inc's Segments
All Other Segments    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.